Roth Mkm Reiterates Buy Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating restated by equities researchers at Roth Mkm in a report released on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock, down from their previous target price of $20.00. Roth Mkm’s price objective points to a potential upside of 318.30% from the company’s previous close.

A number of other research analysts also recently weighed in on the stock. Barclays decreased their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday. Stifel Nicolaus decreased their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday. Royal Bank of Canada dropped their price objective on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. JMP Securities decreased their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday. Finally, B. Riley began coverage on shares of OptimizeRx in a report on Thursday, July 25th. They set a “buy” rating and a $18.50 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.42.

OptimizeRx Stock Performance

Shares of OptimizeRx stock opened at $3.83 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. The firm has a market cap of $70.07 million, a price-to-earnings ratio of -2.88 and a beta of 1.32. OptimizeRx has a one year low of $3.78 and a one year high of $16.65. The stock’s 50-day moving average is $6.60 and its 200-day moving average is $8.99.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of OptimizeRx in the first quarter valued at $542,000. BNP Paribas Financial Markets grew its stake in OptimizeRx by 283.6% in the 1st quarter. BNP Paribas Financial Markets now owns 27,910 shares of the company’s stock valued at $339,000 after buying an additional 20,634 shares during the last quarter. Blair William & Co. IL grew its stake in OptimizeRx by 5.6% in the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after buying an additional 41,469 shares during the last quarter. Vanguard Group Inc. raised its holdings in OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after acquiring an additional 6,291 shares during the period. Finally, First Light Asset Management LLC lifted its position in OptimizeRx by 0.6% during the first quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock worth $21,112,000 after acquiring an additional 10,286 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.